(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -9.01% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Biontech Se's revenue in 2025 is $3,665,697,674.On average, 25 Wall Street analysts forecast BNTX's revenue for 2025 to be $677,122,547,200, with the lowest BNTX revenue forecast at $617,730,051,050, and the highest BNTX revenue forecast at $849,288,649,400. On average, 24 Wall Street analysts forecast BNTX's revenue for 2026 to be $659,328,843,900, with the lowest BNTX revenue forecast at $431,377,077,300, and the highest BNTX revenue forecast at $875,017,382,550.
In 2027, BNTX is forecast to generate $669,187,517,350 in revenue, with the lowest revenue forecast at $421,758,859,300 and the highest revenue forecast at $917,818,452,650.